T1	Participants 92 99	humans.
T2	Participants 457 534	a randomized study of patients with gastric, pancreatic and colorectal cancer
T3	Participants 605 671	a randomized study of patients with resectable cancer of the colon
T4	Participants 713 785	of patients with malignant melanoma and stage IV carcinoma of the breast
T5	Participants 821 926	of patients with advanced gastrointestinal cancer selective stimulation of the immune system with NED 137
